Filing Flows › Mirum Pharmaceuticals (MIRM) › Q2 2026 › vs Q2 2025
Mirum Pharmaceuticals (MIRM) Q2 2026 vs Q2 2025 (year over year)
Mirum Pharmaceuticals's revenue rose $48.5M (+38%) from $128M in Q2 2025 to $176M in Q2 2026. The biggest changes: Livmarli +$40.6M (+46%); Bile Acid Medicines +$7.9M (+20%).
Mirum Pharmaceuticals, Q2 2026: revenue $176M (+38% year over year), operating margin -24.1%, net loss $67.2M, operating cash flow −$44.3M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Livmarli | $129M | $88.2M | $40.6M | +46% |
| Bile Acid Medicines | $47.5M | $39.6M | $7.9M | +20% |
| Revenue | $176M | $128M | $48.5M | +38% |
| Net loss | $67.2M | $5.9M | $61.4M | 11× |
| Costs & expenses | $243M | $134M | $110M | +82% |
| Operating costs | $219M | $133M | $86.0M | +65% |
| Interest & other, net | $23.0M | $470K | $22.5M | 49× |
| Income tax | $1.7M | $402K | $1.3M | +320% |
| Research & development | $90.5M | $46.1M | $44.5M | +97% |
| SG&A | $81.5M | $63.3M | $18.2M | +29% |
| Other operating costs | $46.8M | $23.4M | $23.4M | +100% |
| Operating cash sources | $81.8M | $12.5M | $69.3M | +555% |
| Depreciation & amortization | $6.9M | $6.1M | $880K | +15% |
| Share-based compensation | $30.6M | $18.5M | $12.1M | +66% |
| Cash used in operations | $44.3M | −$12.0M | $56.3M | — |
| Net loss absorbed | $67.2M | $5.9M | $61.4M | 11× |
| Working capital & other | $14.5M | $6.6M | $7.9M | +119% |
Questions
How much did Mirum Pharmaceuticals's revenue grow year over year in Q2 2026?
Mirum Pharmaceuticals's revenue rose $48.5M (+38%) from $128M in Q2 2025 to $176M in Q2 2026.
What drove Mirum Pharmaceuticals's revenue change in Q2 2026?
Livmarli +$40.6M (+46%); Bile Acid Medicines +$7.9M (+20%).